Q-omics provides the consensus-scored C1QTNF9B profile across patient tissues and cancer cell-line models. C1QTNF9B expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, C1QTNF9B is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, C1QTNF9B RNA expression shows 12,399 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight COAD, BRCA, and THYM as cancer lineages where C1QTNF9B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C1QTNF9B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C1QTNF9B survival associations across molecular data types. C1QTNF9B RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C1QTNF9B RNA expression–survival associations across cancer types. High C1QTNF9B expression shows unfavorable associations in COAD and LGG, but favorable associations in KIRP, READ, PAAD and THCA. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for C1QTNF9B RNA expression.
This table summarizes C1QTNF9B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for C1QTNF9B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C1QTNF9B shows lower tumor expression in BRCA and LUAD and higher tumor expression in PRAD, CHOL, LIHC and KIRC. The BRCA box plot shows higher C1QTNF9B RNA expression in normal versus tumor tissue (log2 FC = −0.332, t-test p < 0.001).
This table shows molecular features associated with C1QTNF9B in patient tissues and cancer cell lines. In patient samples, C1QTNF9B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, C1QTNF9B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and SOFT_TISSUE.
